Era of Dinutuximab: Evolving Treatment Strategies for High-Risk Neuroblastoma

High-Risk Neuroblastoma Treated with Dinutuximab Research Paper .pdf

Download PDF • 3.00MB

Word Count: 5809 Words

Faithful Alinaange | Researcher/Writer

Mansfield High School

Sai Keerthana Hinge | Researcher/Writer 

Oakland Mills High School

Kyle Lee | Researcher/Writer

ong Reach High School 

Khaleelat Olamoyegun | Researcher/Writer

Mount Hebron High School

Madilyn Olivares | Researcher/Writer

Plainfield North High School

Table of Contents

Abstract......................................................................................................................................................2

Introduction.............................................................................................................................................. 3

Overview of Tumors................................................................................................................................ 3

Neuroblastoma........................................................................................................................................ 4

Viable Treatment Options.................................................................................................................... 4

Discussion..................................................................................................................................................6

Topic choice: Our Rationale..................................................................................................................6

Diagnosis................................................................................................................................................... 8

Signs and Symptoms............................................................................................................................. 8

Classification Analysis............................................................................................................................9

Patient Population................................................................................................................................. 11

Treatment Mechanisms........................................................................................................................13

Treatment Effectiveness......................................................................................................................14

Current Research/Clinical Evidence................................................................................................ 15

Analysis and Depth............................................................................................................................... 16

Risks...........................................................................................................................................................16

Limitations of Adverse Effects.......................................................................................................... 17

Neurotoxicity............................................................................................................................................18

Capillary Leak Syndrome.................................................................................................................... 19

Hypotension........................................................................................................................................... 19

Infection................................................................................................................................................... 19

Fever..........................................................................................................................................................20

Pain............................................................................................................................................................20

Impacts.................................................................................................................................................... 22

Major Findings....................................................................................................................................... 22

Limitations.............................................................................................................................................. 22

Research Challenges........................................................................................................................... 24

Accessibility.............................................................................................................................................25

Ethical/Social Deliberations...............................................................................................................26

Ponders....................................................................................................................................................28

Key Takeaways....................................................................................................................................... 29

Relevance................................................................................................................................................ 30

Future Research.....................................................................................................................................30

Conclusion................................................................................................................................................31

Works Cited............................................................................................................................................ 32

Abstract

Neuroblastoma is a type of pediatric cancer that occurs in immature nerve cells, known as neuroblasts, but it is mostly found in adrenal glands, small organs that reside above the kidney (NCI Staff). Neuroblasts, in which neuroblastoma stems, can cause similar issues of rapid growth in the abdomen, chest, neck, or pelvis areas of the body. Neuroblastoma is the most common solid tumor cancer in children, the most common type of pediatric cancer in children less than one year old, and is classified as highly aggressive (Krysaal and Foster). Similarly, “high-risk” neuroblastoma is categorized as patients diagnosed with the addition of metastatic disease. Metastatic disease is a form of cancer that can spread to other parts of the body beyond its origin.  In 2015, the FDA approved dinutuximab as treatment for patients with High-Risk Neuroblastoma. This approval covers the use of dinutuximab for patients after first-line multiagent therapy; multimodality therapies such as surgery, chemotherapy, and radiation therapy for patients who have at least a partial response to the initial treatment given (NCI Staff). Unfortunately, roughly 700 people are diagnosed with neuroblastoma annually in the United States of America. (NCI Staff). The survival rate of high-risk neuroblastoma, even when treated with aggressive types of treatments, is 40-50%.  Utilizing dinutuximab has shown that 73% of patients survive following two years of receiving initial treatment.

Keywords: HR-NBL (High-Risk Neuroblastoma), Segmental Chromosomal Aberrations (SCA), metastatic, Granulocyte-macrophage Colony-stimulating Factor (GM-CSF), Aldesleukin (IL-2), Food and Drug Administration (FDA).

Introduction

Overview of Tumors

Tumors are the result of ungovernable growths which may or may not be cancerous. Such growths can stem from solid tissues like organs, muscles, and bone. According to Medical Oncology expert Dr. Robert J. Mayer in a 2019 publication, tumors can spread to tissues surrounding the origin through blood and lymph systems. 

There are two labels for solid tumors: malignant and benign. Solid malignant tumors are cancerous and can divide uncontrollably and contain cells that can start metastatic tumors in other parts of the body. Benign tumors are masses of non-cancerous cells that oftentimes do not require treatment because they do not spread to other healthy tissues.

Fig 1. Cleveland Clinic. “Tumor”. 2024

As for treatment options for tumors, benign tumors are frequently left without treatment unless they are in vulnerable areas of the body, such as the brain which can cause complications. Malignant tumors, on the other hand, are treated through the means of surgery, embolization, chemotherapy, etc as stated by the nonprofit American Medical Center, Cleveland Clinic in a 2024 research journal.  

Neuroblastoma

Neuroblastoma is regarded as the most common cancer diagnosed in children under the age of one. High-risk neuroblastoma, with the aid of The Children’s Oncology Group’s research in 2021, can be diagnosed when SCA’s are detected. Risk evaluation during diagnosis is crucial for determining what the necessary means of action are when assessing what treatment options are best. Along with the identification of SCA’s, high-risk neuroblastoma is diagnosed when the oncogene MYCN is found, immediately classifying the severity as high-risk and with the addition of being diagnosed after the 18th month mark. Patients diagnosed with low to intermediate-risk neuroblastoma have been estimated, by Pediatric Hematology Oncologist Julie Krystal and Pediatric Oncologist Jennifer H. Foster, to have an overall survival rate of 95% following the 5 years after diagnosis compared to the 60% for patients classified as high-risk in a 2023 report. Regrettably, roughly 50% of all patients diagnosed with neuroblastoma fall under the high-risk category.

Viable Treatment Options

Treatment for this highly aggressive pediatric cancer requires intense, multi-step treatments including chemotherapy, surgery, and stem cell transplants. For high-risk neuroblastoma, many sources indicate dinutuximab as a workable treatment plan. Dinutuximab is a drug used with GM-CSF, IL-2, and 130cis retinoic acid to treat patients diagnosed with the unfortunate condition (NCI Staff, 2025). Combining all materials, dinutuximab, GM-CSF, IL-2, and isotretinoin, it becomes an officially registered treatment option established with the US Food and Drug Administration for the treatment of high-risk neuroblastoma patients. 

Fig 2. St. Jude Children’s Research Hospital. “Neuroblastoma”. Together by St. Jude.org.

While many low- or intermediate-risk cases respond well to treatment, pediatric patients with high-risk disease often need intensive multimodal therapy and still face risks of relapse, long-term complications, and death (National Cancer Institute; Cleveland Clinic). These persistent challenges highlight the importance of studying high-risk neuroblastoma within pediatric oncology.

Research Question:

   How does utilizing and adding dinutuximab to standard post-diagnosis therapy impact the survival and relapse rates in pediatric patients with high-risk neuroblastoma? 

Discussion

Topic Choice: Our Rationale

The choice of high-risk neuroblastoma as an area of investigation is motivated by the fact that this type of tumor is among the deadliest and most aggressive pediatric cancers despite medical advances made in this sphere. High-risk neuroblastoma arises from primitive sympathoadrenal ganglion cells derived from the neural crest and affects predominantly infants and young children. While low- and moderate-risk tumors may be successfully treated by means of chemotherapy, high-risk neuroblastoma should be treated using multimodality and aggressive therapies and is usually accompanied by high risks of relapse, toxicities, complications, and even mortality (National Cancer Institute; Cleveland Clinic). As a whole group, we aimed to understand how treatment strategies vary among patients and how factors such as response to therapy, side effects, and individual necessities influence clinical decisions. Examining these differences shows that successful cancer treatment goes beyond destroying cancer cells; it also involves careful consideration of each child’s overall health, quality of life, and therapy tolerability.

• I was interested in how treatment options for one of the most common childhood cancers varied from patient to patient. I wanted to know how allergies, side effects, or cultural differences influenced how a treatment like dinutuximab is administered.

  
  

• Having experienced being diagnosed and admitted into the hospital for a neurological disorder as a child, this topic seems very close to my heart. Waiting through long days in a lone hospital bed was agonizing until I discovered that my condition could be cured; I felt ecstatic. Spreading awareness of this condition seems to me the best way I can help other children and people feel confident in their health improvement. Through concise research, I want to share even a little more information to better advocate for pediatric patients. 

Diagnosis

Signs and Symptoms

Diagnosis involves a myriad of factors, including patient background, tumor data, and chromosomal abnormalities. Due to the condition’s broad effect in the body, signs and symptoms can vary according to the affected region.  Localized neuroblastoma provides minimal display of symptoms, which indicates clearer signs depicted in regional and metastatic neuroblastoma.

Adrenal Gland and Stomach: The condition may cause a painless abdominal mass and bowel movement abnormalities. Additional symptoms surrounding this portion of the body include belly pain and a mildly noticeable lump beneath the skin without tenderness at the touch (Mayo Clinic, 2025). 

Chest and Neck: The condition may cause irritation, inducing wheezing, breathing difficulties, and changes to eye structure. Other common symptoms in the highlighted body section include swelling. Specifically, eye structure changes can appear to be bulging or bruising and rapid muscle twitches surrounding the eyes (opsoclonus myoclonus) (American Cancer Society, 2025). 

Spine: The condition can prompt back pain from nerve compressions, difficulties with bowel movement/urination, and muscle fatigue surrounding the legs. In the case of spinal cord compression associated with the condition, immediate medical attention must be sought. If treated without haste, the symptoms can lead to permanent paralysis (Canadian Cancer Society, 2020). 

 Metastatic neuroblastoma is known as the distant spread of the condition, causing symptoms such as bone pain, dark circles around the eyes, fever, fatigue, painless lumps under the skin, and lack of regular weight growth (Mayo Clinic). According to a study by the International Neuroblastoma Risk Group, the typical age of diagnosis for the condition is between 18 months and 5 years of age (Colon and Chung). 

Classification Analysis

To classify and understand disease severity, physical examinations and imaging tests are conducted with various forms of medical equipment. Computerized tomography (CT) scans and magnetic resonance imaging (MRI) scans are used to measure tumor size and metastasis in the chest, abdomen, and pelvis. 123I-MIBG scans involve injecting a minuscule amount of radioactive iodine associated with the neuroblastoma chemical MIBG to identify tumorous cells. In 10-15% of cases, MIBG may not be an effective diagnostic measure, which requires positron emission tomography (PET) scans to recognize neuroblastoma metastasis by injecting a radiation compound into the patient. Bone marrow testing allows for content removal from the hip bone through aspiration, allowing for suction from a small needle, or biopsy, cutting a minuscule piece in the region under anesthesia. The tumor develops an excess amount of the hormone catecholamine, which can be measured in the urine through Urine VMA/HVA testing. Tissue biopsy provides the final confirmation for diagnosis, enabling treatment selection and identification of certain mutations. (CHOP) To determine classification before treatment, the International Neuroblastoma Risk Group Staging System can be used with two localized stages (L1 and L2) and two metastatic stages (M and MS). Stage L1 contains a locoregional tumor without IDRFs (image-defined risk factors), stage L2 is a locoregional tumor with one or more IDRFs, stage M holds a metastatic condition, and stage Ms is a stage L1 or L2 tumor with a metastatic condition limited to the skin/liver/bone marrow. Image-defined risk factors are essential to identifying tumor proximity to a major organ, thus providing information for surgical preparation (INRGDB).

Patient Population

High-Risk Neuroblastoma primarily impacts patients aged 18 months or older. Rare cases involve strong genetic markers in those younger than 18 months. (Colon and Chung) The condition is prevalent throughout the world, accounting for 8-10% of pediatric cancers and involving approximately 15% of pediatric cancer mortalities. A study conducted by authors in the National Institute of Health, based on data from the Global Burden of Disease (GBD) examined neuroblastoma prevalence among children aged 0-14 across 204 countries in 2021. Nationally, India maintained the highest number of neuroblastoma cases-685. The socio-demographic index portrayed the greatest prevalence of neuroblastoma in low-, low-middle, and middle- index regions. Children aged 10-14 years displayed the lowest incidence levels-6.3% globally (Nong et.al).

Fig 3. National Library of Medicine. “Global, regional, and national epidemiology of childhood neuroblastoma (1990–2021): a statistical analysis of incidence, mortality, and DALYs”. PubMed Central, 2024. 

Patients who are diagnosed with High-risk Neuroblastoma are pediatric patients commonly around 18 months and older. The majority of the patients who are diagnosed with High-risk Neuroblastoma are pediatric patients who are in early childhood. Additionally, 90% of all high–risk neuroblastoma cases are diagnosed before the patients become 10 years old. Males also tend to develop high-risk neuroblastoma more than females do because males are more commonly diagnosed with this type of pediatric cancer (Krystal and Foster).

Fig 4. National Library of Medicine. “Global, regional, and national epidemiology of childhood neuroblastoma (1990–2021): a statistical analysis of incidence, mortality, and DALYs”. PubMed Central, 2024. 

Treatment Mechanisms

Dinutuximab, known as a monoclonal antibody, serves as the primary treatment mechanism for high-risk neuroblastoma. It is lab-generated from the combination of a human IgG1 antibody and anti-GD2 antibody 14G2. Often overexpressed and located on neuroblastoma cells to bind tumor cells, disialoganglioside GD2 is the antigen targeted by dinutuximab. To inhibit cancer metastasis, the antibody depends on individual patient immune mechanisms. Leading to neuroblastoma cell lysis, dinutuximab binds to the GD2 surface and develops immune responses through the antibody-dependent cellular cytotoxicity (ADCC) and the complement-dependent cytotoxicity (CDC). In both processes, antibodies attach to target cells and use cytotoxic effector cells to destroy them. (Mastrangelo, et.al) In a hospital, 17.5 mg/m² of dinutuximab is given through an intravenous infusion (IV) over the course of 10 to 20 hours consecutively for four days. This is also dependent on the patient’s body surface area (aetna). Patients who have undergone multimodal therapy, including chemotherapy, surgery, and autologous stem cell transplantation, are qualified to receive the treatment. They must have gained a response to treatment methods to be administered the antibody (Hernadfoi et al.). In the present day, the FDA approved dinutuximab to treat patients with high-risk neuroblastoma. As indicated prior, the patient must have experienced first-line multimodality therapy (NCI). 

Treatment Effectiveness

The immunotherapy drug Dinutuximab (Unituxin) is proven to extend the lives of children living with high-risk neuroblastoma. 1,183 pediatric patients diagnosed with neuroblastoma participated in a clinical trial in which they were treated with Dinutuximab, given alongside two immune-boosting compounds and isotretinoin (Wang). After 5 years, a majority experienced event-free survival; when a patient is alive and free of tumor growth or recurrence. 2 years after the treatment showed 69% event-free survival and 84% survival overall, and 5 years after the treatment time showed 61% of the children event-free while 72% experienced overall survival (Wang). 

Fig 5. National Cancer Institute. “Study Confirms Dinutuximab Extends Life for Children with High-Risk Neuroblastoma”. Linda Wang, 2022. 

Research conducted and supported by Ami V. Desai, a pediatric oncologist from the University of Chicago, shows that tandem transplants have a higher rate of success than a single transplant. Combining this form of treatment with dinutuximab, however, was shown to be less effective, with a common symptom being pain. Following this observation, it has been concluded that dinutuximab is an effective treatment method when done without surgeries in rapid succession happening simultaneously. 

Current Research/Clinical Evidence

Current research from the Global Burden of Disease has shown that patients with high-risk neuroblastoma have significantly improved survival rates as compared to the 1990s. The shift is evident, with a show of 10 to 20% probability of survival to over 50% in modern day. This is attributed to the development of effective treatments over the span of three decades. Each year, there are approximately 5560 diagnosed cases of neuroblastoma worldwide. The average age of diagnosis is 17-18 months and 90% of diagnoses occur for patients under five years of age. The highest incidence rates of neuroblastoma were found in children under one year of age, holding 25.4% of diagnosed cases in 2021. Whereas children of 10-14 years reported the lowest rates of incidence, holding 6.3% of diagnosed cases in 2021(Nong, et.al). Studies conducted in the Journal of Clinical Oncology found that dinutuximab beta enables a significant reduction in tumors following six cycles of treatment. This is particularly beneficial in addition to chemotherapy, evident in improved objective response rates among patients.

Analysis and Depth

Risks

High-risk neuroblastoma is classified under stage M of the International Neuroblastoma Risk Group staging system. Patients may face relapse or refractory disease even with multiagent and high-dose chemotherapy, enabling few effective treatment options. Those who complete treatments may experience hearing loss, growth delays, fertility issues, and potential malignancy. Platinum-based chemotherapy serves as the primary contributor to hearing loss among patients, increasing chances of learning setbacks and social disabilities. Similar to many pediatric cancers, the condition develops risk of pulmonary and cardiac diseases due to exposure to chest radiotherapy, anthracycline chemotherapy, and busulfan. Treatment intensity leads to high levels of subsequent malignant neoplasms, known as secondary cancers, among survivors of high-risk neuroblastoma. Moreover, patients maintain higher chances of developing endocrinopathies, including hypothyroidism and hypogonadism. Stem cell transplantation increases exposures that lead to substandard linear growth and height. Testicular or ovarian gonadal failure derives from endocrine-based issues. As a result of early exposure to the condition, female patients may experience absent or delayed puberty (Dubois, et.al).

Fig 6. ASCO Publications. “High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes”. DuBois et,al, 2022. 

Limitations of Adverse Effects

Multiple severe side effects were associated with the dinutuximab combination, including neurotoxicity, allergic reactions, pain, infection, capillary leak syndrome, fever, and low blood pressure. The wide range of variability and severity of these adverse effects limit researchers' ability to generalize findings across all neuroblastoma patients. Dose reductions and study withdrawals occur as a result of treatment toxicities, which leaves the remaining data to be skewed towards more resilient subgroups. In addition, the heterogeneity across patients and tumors causes unpredictable side-effect manifestations across diverse ages and genetic profiles (National Cancer Institute).

Neurotoxicity 

When exposure to a natural or manmade toxic substance alters the normal functioning of the nervous system, leading to the disruption or even destruction of neurons (Cleveland Clinic). During the process of immunotherapy, the nervous system can face this damage when inflammatory chemicals or supercharged immune cells cause harm to the brain, spinal cord, or peripheral nerves. The two primary types of immunotherapy-induced neurologic toxicities are ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome) and irAEs (Immune-Related Adverse Events) (Sato et al.). ICANS, driven by blood-brain barrier breakdown and cytokine surges, is presented through symptoms like confusion, aphasia, and tremors. Driven by a loss of immune tolerance attacking neural tissue, neurological irAEs can be presented through symptoms such as encephalitis (brain inflammation), myasthenia gravis (an autoimmune disorder that disrupts communications between nerves and muscles), or peripheral neuropathies (damage to nerves outside the spinal cord and brain). Neurotoxicity is managed during immunotherapy by preventative pain control applied through intravenous opioids or oral gabapentin, neurological monitoring, and dose changes in

response to reaction severity (Barone et al.).

Capillary Leak Syndrome

A side effect of dinutuximab immunotherapy where low blood pressure, swelling, and reduced urine output are caused by fluid and protein leakage from blood vessels into surrounding tissues. Symptoms of Capillary Leak Syndrome (CLS) may include hypotension, edema (swelling in hands, feet, or ankles), decreased intravascular volume, and decreased urine output (Armideo et al.). This side effect is managed through monitoring fluid balance, hemodynamic stability,  respiratory patterns, and infusion rate adjustments depending on the symptom severity (Secola et al.).

Hypotension

Caused by systemic vasodilation, capillary leak syndrome, or acute infusion reactions, Hypotension (low blood pressure) is a common side effect of Dinutuximab immunotherapy, with up to a 60% occurrence in patients (Armideo et al.). Common warning signs of hypotension are lightheadedness, fainting, nausea, extreme exhaustion, or breathing changes (Mayo Clinic). If a patient experiences hypotension during dinutuximab treatment, the infusion should immediately stop, and volume resuscitation (administration of plasma, blood, or other intravenous fluids to restore normal blood circulation and blood pressure) should be rapidly initiated. Other common management procedures for this side effect include proactive prehydration through about 10 mL saline infusions one hour before dinutuximab doses, clinical monitoring of vital signs, and dinutuximab infusion rate adjustments (Wheaton and Zalan).

Infection

During dinutuximab treatment, infection occurs primarily due to myelosuppression (bone marrow suppression, which suppresses the bone marrow's ability to produce healthy white blood cells. This leaves the body vulnerable to bacterial, viral, and fungal pathogens. Central venous catheters also cause infection risk as patients receiving continuous intravenous infusions face vulnerability to device-related infections through the use of central lines or ports, which can become direct entry points for skin bacteria into the bloodstream (Blom et al.). Common signs of infection are fever and chills, respiratory issues, urinary discomfort, and wound problems (itching, soreness, reddening) (Li and Zheng). The medical management of an infection amidst immunotherapy treatment requires the immediate interruption of the infusion, diagnostic workup to identify the specific invading pathogen, and promptly initiated antimicrobial therapy through the use of antibiotics, antivirals, and antifungals. 

Fever

There is an immune overstimulation that happens as a result of the infusion of the dinutuximab antibody. This activates the immune system, leads to the release of cytokines (a type of signaling protein), and results in the reset of the brain's thermostat. A fever can occur during or hours after the infusion process as a result of this overstimulation. To manage it, blood cultures are sent to rule out possible infection after a patient’s temperature begins to rise, a broad-spectrum antibiotic is given as other infusions are put on hold, and acetaminophen is pre-administered to the patient in anticipation of this common side effect (Armideo et al.).

Pain

Severe neuropathic pain is the most common result of dinutuximab infusions. Disialoganglioside GD2, found on the surface of neuroblastoma cells, is the primary target of dinutuximab. Because it is also expressed on neurons and peripheral sensory fibers, patients may experience neuropathic pain anywhere throughout the body (Yu et al.). In anticipation of this side effect, patients receive both a required IV bolus of a narcotic pain medication and a patient-controlled analgesia (PCA) infusion approximately 30 minutes before starting dinutuximab each day (Armideo et al.). Managing pain during the immunotherapy process requires a multimodal approach that relies on combining non-opioid pain relievers, nerve-pain medications, and pre-administered intravenous opioids delivered through methods like PCA.

Impacts

Major Findings

In 2015, the Food and Drug Administration (FDA) approved the use of dinutuximab as the primary form of therapy for pediatric cases of neuroblastoma. Dinutuximab is administered following the use of multimodality therapy such as surgery, chemotherapy, and radiation therapy (NCL, 2015).

Following three decades of constant treatment adjustment and improvement, including dinutuximab, positive response rates have climbed from 18.2% to 30.2% (Gray, J.C. et.al). Overall, with the now foundational use of dinutuximab as a form of combined treatment, survival rates are increasing and in the near future, a permanent cure may be discovered that has an epically low rate of recurring symptoms. 

Limitations

Though Dinutuximab serves a pivotal role in treatment methods, certain eligibility requirements inflict limitations on patients. This is highly dependent on the patient’s medical background and prior treatments. Disease progression prior to the GD2 antibody therapy and doses exceeding 17.5 mg/m² past 5 cycles enable restrictions to the treatment (molinahealthcare). Long term-effects of the antibody have shown improved survival rates. However, rare cases of dinutuximab beta therapy exposure may increase liver transaminase, hypoalbuminemia, and reduce blood count parameters. These effects are applicable in accordance with cytotoxic therapies (Achbergerova et.al). Furthermore, many patients experience cost and accessibility concerns due to high drug prices in the global market. On average, a complete treatment based on dinutuximab costs approximately $192,750. This significantly disrupts equal global access due to disparities between socio-economic classes. In a study conducted among 100 facilities across 59 countries, anti-GD2 therapy treatment was accessible in 93% of high-income centers and 21% in low-income centers (Papyan et.al). In spite of extensive research conducted on the effectiveness of dinutuximab on pediatric patients, certain questions remain unanswered. The addition of cytokines can aid in tumor lysis when combined with dinutuximab, but the significance remains unsettled. Moreover, the ideal infusion rate of anti-GD2 antibodies needs to be determined to address tolerability, which is currently being tested in international clinical trials (Dr. Reaman).

Fig 7. National Library of Medicine. “Dinutuximab beta in the treatment of high-risk neuroblastoma”. Achbergerová et.al, 2022. 

Research Challenges

Research challenges within the study of dinutuximab immunotherapy are adverse events, patient resistance or relapse, and treatment delivery optimization. 

Adverse events present a major challenge in the study of Dinutuximab because they cause severe physical distress, are diagnostically difficult to identify, and lead to complicated combinations of treatment protocols that vary from patient to patient (Barone et al.). The resulting pain pediatric patients face limits their treatment tolerance, requiring clinicians oftentimes to slow down, prolong, or stop immunotherapy. Identifying the specific side effect a patient is experiencing can be a complicated process due to the high symptom overlap between disease progression, infections, or the standard toxicity side effects. Pediatric patients' inability to differentiate and quantify neuropathic pain from the standard infusion distress also delays the identification of an adverse event. The combination of dinutuximab with multiple other background agents such as isotretinoin obscures which specific drug is the driving factor behind individual toxicities. The patient heterogeneity in the small pediatric sample sizes filled with children of diverse treatment backgrounds prevents the progression of accurate biomarker studies that help better understand a patient's response to toxicity (Pauken et al.).

Despite its substantial clinical success, over 40% of neuroblastoma patients develop resistance or fail to respond to the anti- GD2 therapy due to antigen loss, immunosuppressive microenvironments, and effector cell impairment (Liu et al.). Antigen loss is when cancer cells reduce the amount or completely discontinue the expression of the GD2 surface antigen, which means the antibody loses its binding target. When the network of cells and signals surrounding a tumor creates a barrier that blocks immune cells from destroying cancer cells, dinutuximab, an antibody that relies on immune cells such as the natural killer (NK), is weakened. In response to chemotherapy, there is a reduction in patients' immune cell counts, leading to an inability to properly recognize, bind to, and destroy cancer cells. Lack of response to the treatment and eventual relapse are among the primary research and clinical challenges within the study of Dinutuximab immunotherapy that are being fought with combinations that could potentially overcome resistance barriers and alternative anti-GD2 agents like dinutuximab beta or naxitamab (Furman).

The need to balance severe neuropathic pain with precise dosing schedules and patient quality of life poses treatment delivery optimization as a major research challenge to Dinutuximab immunotherapy.  To mitigate severe neuropathic pain during treatment, a co-administration of intravenous infusions of opioids or gabapentin by mouth needs to occur. Researchers must find a way to balance pain medication protocols in a way that maintains therapeutic efficiency without overwhelming a patient's tolerance. The duration of an infusion also affects the amount of pain a patient faces and the overall efficacy of the medication. Standardized short-term infusions result in pain spikes as a response to the toxicity, whereas long-term infusions (around 10 days) significantly reduce pain toxicity while sustaining the immune activity of the patient (Wheaton et al.). 

Accessibility

Over 200 children's hospitals and specialized cancer centers across the United States and Canada experience the distribution of Dinutuximab (Unituxin), with over 6,000 healthcare providers across these institutions that have been professionally trained to safely and effectively administer this treatment (Unituxin). Despite this, accessibility to Dinutuximab immunotherapy is still very highly restricted because it requires complex oncology infrastructure and prior insurance or financial clearance for a high-cost biological medication. 

The delivery of this treatment requires 10- to 20-hour intravenous infusions multiple times a day. This needs to be administered alongside continuous pain management infusions to deal with the neuropathic side effects. With a nearly 100% probability of a patient experiencing adverse events as a response to Dinutuximab immunotherapy (Yalçın et al.), most initial cycles of the treatment are given in a hospital setting where the patient can be closely monitored.

In order to gain approval from a patient’s health insurance provider, extensive documentation of diagnosis, phase of treatment, and logistical coordination is required beforehand and can often become an access barrier to the patient receiving treatment. The baseline cost for a full multi-cycle course of anti-GD2 therapy for the dinutuximab drug alone ranges from $140,000 to $190,000. This highlights the substantial financial burden these therapies would impose on families who go through with the treatment. If a family chooses to rely on their health insurance, prior authorization for treatment is only granted after the pediatric oncologist provides clinical notes that prove the pediatric patient is under 21 years old, has high-risk neuroblastoma, and has achieved at least some form of response to first-line induction therapy. Once these oncology notes are received, the time required for companies to go through and complex oncology protocols can stall critical maintenance therapies that could have already been underway (Jones et al.). If a physician prescribes a non-standardized dinutuximab combination to improve a patient’s response to treatment, insurers may also deny coverage under the belief that it is investigational, forcing a lengthy appeal process defending a style of treatment that could ultimately benefit the patient.

Ethical/Social Deliberations

Ethical and Social considerations surrounding treating high-risk neuroblastoma with the dinutuximab drug include proxy decision-making, equitable access, and family quality of life. 

According to the American Cancer Society, neuroblastoma is the most common cancer diagnosed in a child during their first year of life, and about 75% to 89% of all neuroblastoma patients are diagnosed before the age of 5. Since infants and young children are the predominant patients, their parents are often left with the decision of consenting to painful treatment plans and regimens without the full comprehension of the child who must undergo it.

Dinutuximab treatment consists of 5 total treatment cycles that average a total length of 4 to 6 months (Cabral et al.). All throughout this time, a patient should go through specialized immunotherapy, inpatient monitoring, and specialized pain management. 65% of treatment centers in low- and middle-income countries completely lack access to anti- GD2 immunotherapies due to high costs with no compensation. In comparison to 93% in high-income countries, only 21% of LMICs (low- and middle-income countries) offer frontline maintenance with anti-GD2 therapy. This is due to the economic advantage high-income countries have, as they rely on government or insurance coverage; meanwhile, low-income regions are forced to rely on funds that come almost entirely from out-of-pocket payments or charity support (Papyan et al.).

The treatment cycles of immunotherapy often result in a disruption to the lives of the families affected by it. A family’s stability, including parental employment, educational development of patients and siblings, and the social development of patients and siblings, can all be heavily affected by a continuous pattern of prolonged hospital visits and outpatient infusions. A child experiencing the intensive treatment will face long-term social and educational interruptions during critical formative years due to the active treatment cycles shadowing their early stages of development. Long-term resilience from survivors of neuroblastoma and their families is still met with aftereffects such as lingering anxiety about relapse or future health issues (Tan et al.).

Ponders

Remaining questions in the study of high-risk neuroblastoma being treated with dinutuximab are treatment optimization through most effective dosing strategies, clarity on the benefits of drug combinations, and long-term impacts faced by survivors. 

In a recent St. Jude study that used the newer anti-GD2 variant known as hu14.18K322A, it has been unclear whether its better-yielding results in comparison to dinutuximab are due to its higher dose magnitude or because it is a better antibody (St. Jude Children’s Research Hospital). In the further assessment of optimal dosing, researchers are working to clarify if an earlier timing of Dinutuximab administration improves survival rates compared to it being given in the standard post-consolidation phase. Furthermore, in order to maximize anti-tumor efficacy while effectively mitigating neuropathic pain, the length of dosing periods during infusion is being refined into more continuous lengths instead of short-term (Ladenstein).

The use of cytokines within Dinutuximab immunotherapy is to boost the patient's immune system so it can better find and destroy cancer cells. In an attempt to better understand how to utilize cytokines, researchers are trying to clarify whether co-administering them increases survival benefits, or only increases toxicity. It is also being determined how to treat tumors that downregulate or altogether resist anti-GD2 combinations. To fight against relapse,  multi-agent combinations could potentially be used for patients who progress despite dinutuximab exposure being explored as well. Common antibody-chemotherapy combinations are TEMIRI, TOTEM, or HITS (Raiser et al.).

Since Neuroblastoma is a pediatric cancer, the effects of dinutuximab immunotherapy on pediatric patients could have long-term or even lifelong impacts on their growth and development. Post-treatment growth that tracks standard pediatric measurements (height, weight, body mass) in addition to skeletal maturation and hormone screening requires continual long-term surveillance to decipher relationships between growth patterns and treatment history of recovered neuroblastoma patients. Chronic health outcomes of pediatric survivors are being further studied as well, with current studies showing noticeable rates of autoimmune disease and chronic diarrhea present in survivors attributed to the antibody treatment (Flaadt et al.).

Key Takeaways

The monoclonal antibody dinutuximab acts by binding to the molecule labeled as GD2. GD2 is a disialoganglioside molecule, a tumor-associated antigen in regard to cancer that can be found on cell membranes. 

Regardless of the recent introduction of dinutuximab as treatment, it has already shown prominent signs of effectiveness, with 73% of patients surviving beyond two years of initial treatment compared to 58% without its use (NCL, 2015). 

Confirmed through hundreds upon hundreds of trials, it has been proven in 2022 that dinutuximab is a viable treatment option to elongate the life of patients diagnosed with high-risk neuroblastoma. The first stages of the trials provided evidence that the combination of dinutuximab with other existing treatments following the 2015 FDA approval led to the accumulation of patients who had no evidence of recurring symptoms two years after initiating the new treatment (Wang, 2022). 

Relevance

Since its approval by the FDA in 2015, dinutuximab has proven time and time again that it can elongate the lifespan of pediatric patients diagnosed with the condition, high-risk neuroblastoma. This is crucial to run more trials in the hopes of finding a cure or another method to better the quality of life a patient can have and to lead to interconnected macrodiscoveries that can be used to treat other conditions with similar characteristics. In addition, the use of dinutuximab has shown many cases of relapse prevention, minimizing residual disease in patients beyond treatment and recovery (ASCO Post Staff, 2016). 

Future Research

In Hungarian clinical trial settings, there is evidence of multiple cases of initial misdiagnoses. When research is completed by Márk Hernádfői et. al, rural diagnostic delays in pediatric oncology clinics may be reduced drastically, providing a method to systematically diagnose a patient rapidly to evaluate optimal treatment options. In extension, this can lead to higher survival rates because treatment options can be personalized sooner. In conclusion, with the success of future trials, the efficacy of testing different dinutuximab variations for different patient types can be improved, leading to branching discoveries and improved rates of patient survivability and quality of life (Márk Hernádfői et. al, 2025).

Conclusion

High-Risk Neuroblastoma is the most common pediatric cancer diagnosed in patients younger than 12 months. An aggressive form of cancer that categorizes roughly half of its carriers as high-risk, in addition, giving a less than desired survivability rate beyond five years once diagnosed. Yet, after decades of research and fine-tuning treatment options, dinutuximab, a drug, has been applied in clinical trials and has so far been successful. In its success, raising the survival rate beyond two and five years, respectively. Pediatric high-risk neuroblastoma requires more research to ensure patients can receive optimized treatment that is specific to any underlying conditions that may be present.

Overall, our research presents what is currently known and understood of the condition, how it impacts patients, and what can be continued to work on. Real-life application of our research lies in advocacy and awareness, providing information to detect symptoms soon, and supporting ongoing research to drive for acclimated treatments with the use of dinutuximab. Future research in multiple aspects should focus on early detection without misdiagnoses to refine treatment mechanisms, reduce recurring symptoms, and to improve the overall quality of life of all affected by this condition, especially pediatric patients. 

Works Cited 

Achbergerová, Monika, et al. "Dinutuximab Beta in the Treatment of High-risk Neuroblastoma." Medicine, vol. 101, no. 4, 28 Jan. 2022, p. e28716, https://doi.org/10.1097/md.0000000000028716. Accessed 29 July 2026.

Aetna. "Dinutuximab (Unituxin)." aetna, 23 Oct. 2025, www.aetna.com/cpb/medical/data/800_899/0895.html. Accessed 29 July 2026.

American Cancer Society. "Signs and Symptoms of Neuroblastoma." Cancer.org, 26 June 2025, www.cancer.org/cancer/types/neuroblastoma/detection-diagnosis-staging/signs-and-symptoms.html. Accessed 29 July 2026.

The APSO Post Staff. "Approval of Dinutuximab for High-Risk Neuroblastoma: Lessons Learned in Expediting the Development of Pediatric Cancer Drugs." The ASCO Post, Dec.-Jan. 2016, ascopost.com/issues/december-10-2016/approval-of-dinutuximab-for-high-risk-neuroblastoma-lessons-learned-in-expediting-the-development-of-pediatric-cancer-drugs/. Accessed 29 July 2026.

Armideo, RN, CRNP, et al. "Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications." Journal of the Advanced Practitioner in Oncology, vol. 8, no. 1, 1 Feb. 2017, https://doi.org/10.6004/jadpro.2017.8.1.4. Accessed 29 July 2026.

Bagatell, Rochelle. "Hereditary Neuroblastoma." Children's Hospital of Philadelphia, www.chop.edu/conditions-diseases/hereditary-neuroblastoma. Accessed 29 July 2026.

Barone, Giuseppe, et al. "Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance." Pediatric Drugs, vol. 23, no. 6, 20 Sept. 2021, pp. 537-48, https://doi.org/10.1007/s40272-021-00469-9. Accessed 29 July 2026.

Blom, Thomas, et al. "Treatment-Related Toxicities during Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients." Frontiers in Oncology, vol. 10, 17 Feb. 2021, https://doi.org/10.3389/fonc.2020.601076. Accessed 29 July 2026.

Boston's Children Hospital. "Neuroblastoma." Boston's Children Hospital, www.childrenshospital.org/conditions-treatments/neuroblastoma. Accessed 29 July 2026.

Campos Cogo, Sheron, et al. "An Overview of Neuroblastoma Cell Lineage Phenotypes." Experimental Biology and Medicine, vol. 245, no. 18, 12 Aug. 2020, pp. 1637-47, https://doi.org/10.1177/1535370220949237. Accessed 29 July 2026.

Canadian Cancer Society. "Symptoms of neuroblastoma." Cancer.ca, Jan. 2020, cancer.ca/en/cancer-information/cancer-types/neuroblastoma/signs-and-symptoms. Accessed 29 July 2026.

Cleveland Clinic. "Neuroblastoma." Cleveland Clinic. Cleveland Clinic, my.clevelandclinic.org/health/diseases/14390-neuroblastoma. Accessed 29 July 2026.

Colon, Nadja C., and Dai H. Chung. "Neuroblastoma." Advances in Pediatrics, vol. 58, no. 1, 2011, pp. 297-311, https://doi.org/10.1016/j.yapd.2011.03.011. Accessed 29 July 2026.

Cupit-Link, Margaret, and Sara M. Federico. "Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in All Cycles of Induction." Cancers, vol. 15, no. 18, 18 Sept. 2023, p. 4609, https://doi.org/10.3390/cancers15184609. Accessed 29 July 2026.

D'Hebron, Vall. "An international clinical trial demonstrates the benefit of combining chemotherapy and immunotherapy in the treatment of neuroblastoma." BioTech, 13 Feb. 2026, biotech-spain.com/en/articles/an-international-clinical-trial-demonstrates-the-benefit-of-combining-chemotherapy-and-immunotherapy-in-the-treatment-of-neuroblastoma/. Accessed 29 July 2026.

DuBois, Steven G., et al. "High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes." American Society of Clinical Oncology Educational Book, no. 42, July 2022, pp. 768-80, https://doi.org/10.1200/edbk_349783. Accessed 29 July 2026.

---. "High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes." American Society of Clinical Oncology Educational Book, no. 42, July 2022, pp. 768-80, https://doi.org/10.1200/edbk_349783. Accessed 29 July 2026.

Escalante Romero, Lorena, et al. "Efficacy and Safety of the Use of Dinutuximab in Newly Diagnosed or Relapse High Risk Neuroblastoma: Single Arm Systematic Review and Meta-analysis." Journal of Clinical Oncology, vol. 42, no. 16_suppl, 1 June 2024, p. 10044, https://doi.org/10.1200/jco.2024.42.16_suppl.10044. Accessed 29 July 2026.

European Journal of Cancer. 2024, www.ejcancer.com/article/S0959-8049(24)00157-6/fulltext. Accessed 29 July 2026.

Flaadt, Tim, et al. "Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment including Anti-GD2 Immunotherapy: A Retrospective Cohort Study." Cancers, vol. 17, no. 1, 5 Jan. 2025, p. 149, https://doi.org/10.3390/cancers17010149. Accessed 29 July 2026.

Furman, Wayne L. "Monoclonal Antibody Therapies for High Risk Neuroblastoma." Biologics: Targets and Therapy, vols. Volume 15, June 2021, pp. 205-19, https://doi.org/10.2147/btt.s267278. Accessed 29 July 2026.

---. "Monoclonal Antibody Therapies for High Risk Neuroblastoma." Biologics: Targets and Therapy, vols. Volume 15, June 2021, pp. 205-19, https://doi.org/10.2147/btt.s267278. Accessed 29 July 2026.

Hernádfői, Márk, et al. "Dinutuximab Beta for the Treatment of High-Risk Neuroblastoma: Data from the Hungarian Pediatric Oncology Network." Journal of Clinical Medicine, vol. 14, no. 18, 20 Sept. 2025, p. 6641, https://doi.org/10.3390/jcm14186641. Accessed 29 July 2026.

---. "Dinutuximab Beta for the Treatment of High-Risk Neuroblastoma: Data from the Hungarian Pediatric Oncology Network." Journal of Clinical Medicine, vol. 14, no. 18, 20 Sept. 2025, p. 6641, https://doi.org/10.3390/jcm14186641. Accessed 29 July 2026.

Hesko, Caroline, et al. "Neurocognitive Outcomes in Adult Survivors of Neuroblastoma: A Report from the Childhood Cancer Survivor Study." Cancer, vol. 129, no. 18, 18 May 2023, pp. 2904-14, https://doi.org/10.1002/cncr.34847. Accessed 29 July 2026.

Hoy, Sheridan M. "Dinutuximab: A Review in High-Risk Neuroblastoma." Targeted Oncology, vol. 11, no. 2, 19 Feb. 2016, pp. 247-53, https://doi.org/10.1007/s11523-016-0420-2. Accessed 29 July 2026.

INRG Staging System. "INRGSS: International Neuroblastoma Risk Group Staging System." INRG, inrgdb.org/neuroblastoma-information/staging-system/. Accessed 29 July 2026.

Keyel, Michelle E., and C. Patrick Reynolds. "Spotlight on Dinutuximab in the Treatment of High-risk Neuroblastoma: Development and Place in Therapy." Biologics: Targets and Therapy, vols. Volume 13, Dec. 2018, pp. 1-12, https://doi.org/10.2147/btt.s114530. Accessed 29 July 2026.

Krystal, Julie, and Jennifer H. Foster. "Treatment of High-Risk Neuroblastoma." Children, vol. 10, no. 8, 28 July 2023, p. 1302, https://doi.org/10.3390/children10081302. Accessed 29 July 2026.

---. "Treatment of High-Risk Neuroblastoma." Children, vol. 10, no. 8, 28 July 2023, p. 1302, https://doi.org/10.3390/children10081302. Accessed 29 July 2026.

Lerman, Benjamin J., et al. "Progression-Free Survival and Patterns of Response in Patients with Relapsed High-Risk Neuroblastoma Treated with Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor." Journal of Clinical Oncology, vol. 41, no. 3, 20 Jan. 2023, pp. 508-16, https://doi.org/10.1200/jco.22.01273. Accessed 29 July 2026.

Lode, Holger N., et al. "Dinutuximab Beta vs. Historical Controls in the Maintenance Therapy of Relapsed Neuroblastoma: Unadjusted and Adjusted Indirect Comparison." ISPOR, vol. 28, no. S2, 2025, www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2025/poster-session-2-2/dinutuximab-beta-vs-historical-controls-in-the-maintenance-therapy-of-relapsed-neuroblastoma-unadjusted-and-adjusted-indirect-comparison#:~:text=CONCLUSIONS:%20Dinutuximab%20beta%20significantly%20extends,unadjusted%20and%20adjusted%20indirect%20comparisons. Accessed 29 July 2026.

Mastrangelo, Stefano, et al. "Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients." International Journal of Molecular Sciences, vol. 22, no. 23, 23 Nov. 2021, p. 12648, https://doi.org/10.3390/ijms222312648. Accessed 29 July 2026.

Mayer, Robert J. "Tumor vs Cancer: What You Need to Know." Dana-Farber Cancer Institute, 16 May 2018. Dana-Farber Cancer Institute, blog.dana-farber.org/insight/2018/05/difference-cancer-tumor/. Accessed 29 July 2026.

MAYO Clinic. "Neuroblastoma." MAYO Clinic, www.mayoclinic.org/diseases-conditions/neuroblastoma/symptoms-causes/syc-20351017. Accessed 29 July 2026.

Mohd, Ahmed Bassam, et al. "Safety and Efficacy of Dinutuximab in the Treatment of Neuroblastoma: A Review." Journal of Research in Medical Sciences, vol. 28, no. 1, Sept. 2023, https://doi.org/10.4103/jrms.jrms_727_22. Accessed 29 July 2026.

Mora, Jaume. "Dinutuximab for the Treatment of Pediatric Patients with High-risk Neuroblastoma." Expert Review of Clinical Pharmacology, vol. 9, no. 5, 21 Mar. 2016, pp. 647-53, https://doi.org/10.1586/17512433.2016.1160775. Accessed 29 July 2026.

---. "Dinutuximab for the Treatment of Pediatric Patients with High-risk Neuroblastoma." Expert Review of Clinical Pharmacology, vol. 9, no. 5, 21 Mar. 2016, pp. 647-53, https://doi.org/10.1586/17512433.2016.1160775. Accessed 29 July 2026.

National Cancer Institute. "Neuroblastoma Treatment (PDQ®)–Health Professional Version." National Cancer Institute, 28 Apr. 2025. Cancer.gov, www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq#top. Accessed 29 July 2026.

NCI Staff. "FDA Approves First Therapy for High-Risk Neuroblastoma." National Cancer Institute, 27 Mar. 2015. National Cancer Institute, www.cancer.gov/news-events/cancer-currents-blog/2015/dinutuximab-neuroblastoma. Accessed 29 July 2026.

Nong, Jusen, et al. "Global, Regional, and National Epidemiology of Childhood Neuroblastoma (1990–2021): A Statistical Analysis of Incidence, Mortality, and DALYs." EClinicalMedicine, vol. 79, Jan. 2025, p. 102964, https://doi.org/10.1016/j.eclinm.2024.102964. Accessed 29 July 2026.

---. "Global, Regional, and National Epidemiology of Childhood Neuroblastoma (1990–2021): A Statistical Analysis of Incidence, Mortality, and DALYs." EClinicalMedicine, vol. 79, Jan. 2025, p. 102964, https://doi.org/10.1016/j.eclinm.2024.102964. Accessed 29 July 2026.

Olgun, Nur, et al. "Dinutuximab Beta plus Conventional Chemotherapy for Relapsed/refractory High-risk Neuroblastoma: A Single-center Experience." Frontiers in Oncology, vol. 12, 23 Dec. 2022, https://doi.org/10.3389/fonc.2022.1041443. Accessed 29 July 2026.

Papyan, Ruzanna, et al. "The Price of Survival: Global Inequities in Anti‐GD2 Immunotherapy for Neuroblastoma." Pediatric Blood & Cancer, vol. 73, no. 4, 23 Jan. 2026, https://doi.org/10.1002/1545-5017.70152. Accessed 29 July 2026.

---. "The Price of Survival: Global Inequities in Anti‐GD2 Immunotherapy for Neuroblastoma." Pediatric Blood & Cancer, vol. 73, no. 4, 23 Jan. 2026, https://doi.org/10.1002/1545-5017.70152. Accessed 29 July 2026.

Pauken, Kristen E., et al. "Adverse Events following Cancer Immunotherapy: Obstacles and Opportunities." Trends in Immunology, vol. 40, no. 6, June 2019, pp. 511-23, https://doi.org/10.1016/j.it.2019.04.002. Accessed 29 July 2026.

Secola, Rita, et al. "The Role of Nursing Professionals in the Management of Patients with High-Risk Neuroblastoma Receiving Dinutuximab Therapy." Journal of Pediatric Oncology Nursing, vol. 34, no. 3, 6 Jan. 2017, pp. 160-72, https://doi.org/10.1177/1043454216680595. Accessed 29 July 2026.

St.Jude Children's Research Hospital. "Neuroblastoma." together.stjude.org, together.stjude.org/en-us/conditions/cancers/neuroblastoma.html?sc_cid=-together_evergreen_traffic_search_neuroblastoma-fy25-google-search-paid-responsive-neuroblastoma_general&gad_source=1&gad_campaignid=22634041372&gbraid=0AAAAACYxWIcsHL69yyVTiKKrgTHpLCBwW&gclid=Cj0KCQjw94bTBhDQARIsAN3vv0za3REkfY5NQeH6paBUBk_cjni64nYhTa2-op2Vm4x3CqsGWvydsooaAk0REALw_wcB. Accessed 29 July 2026.

Study Confirms Dinutuximab Extends Life for Children with High-Risk Neuroblastoma. 6 Sept. 2022. National Cancer Institute, www.cancer.gov/news-events/cancer-currents-blog/2022/study-confirms-dinutiximab-high-risk-neuroblastoma. Accessed 29 July 2026.

Tan, Jessica, et al. "Neuroblastoma Survivors' Self-reported Late Effects, Quality of Life, Health-care Use, and Risk Perceptions." Palliative and Supportive Care, vol. 22, no. 2, 14 June 2023, pp. 296-305, https://doi.org/10.1017/s1478951523000615. Accessed 29 July 2026.

Trahair, T. N., et al. "Long-term Outcomes in Children with High-risk Neuroblastoma Treated with Autologous Stem Cell Transplantation." Bone Marrow Transplantation, vol. 40, no. 8, 27 Aug. 2007, pp. 741-46, https://doi.org/10.1038/sj.bmt.1705809. Accessed 29 July 2026.

University of Birmingham. "Dinutuximab beta plus chemotherapy shrinks neuroblastoma tumors in children." News Medical Life Sciences, 12 Dec. 2025, www.news-medical.net/news/20251212/Dinutuximab-beta-plus-chemotherapy-shrinks-neuroblastoma-tumors-in-children.aspx. Accessed 29 July 2026.

Utilization Management Committee. "Drug Policy: Unituxin™ (dinutuximab)." Molina Healthcare, 12 July 2023, www.molinahealthcare.com/-/media/Molina/PublicWebsite/PDF/Providers/oh/medicaid/policies/Unituxin-dinutuximab-Policy-No-UM-ONC-1387-0624.ashx. Accessed 29 July 2026.

Yalçın, B., et al. "Adverse Events Associated with Dinutuximab-beta Treatment in High-risk Neuroblastoma: Hacettepe Experience." EJC Paediatric Oncology, vol. 7, June 2026, p. 100452, https://doi.org/10.1016/j.ejcped.2025.100452. Accessed 29 July 2026.

Yu, Alice L., et al. "Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma." New England Journal of Medicine, vol. 363, no. 14, 30 Sept. 2010, pp. 1324-34, https://doi.org/10.1056/nejmoa0911123. Accessed 29 July 2026.

Era of Dinutuximab: Evolving Treatment Strategies for High-Risk Neuroblastoma 

Word Count: 5809 Words

Faithful Alinaange | Researcher/Writer Mansfield High School

Sai Keerthana Hinge | Researcher/Writer 

Oakland Mills High School

Kyle Lee | Researcher/Writer Long Reach High School 

Khaleelat Olamoyegun | Researcher/WriterMount Hebron High School

Madilyn Olivares | Researcher/WriterPlainfield North High School

Table of Contents

Abstract 2

Introduction 3

    Overview of Tumors 3

    Neuroblastoma 4

    Viable Treatment Options 4

Discussion 6

    Topic choice: Our Rationale 6

Diagnosis 8

    Signs and Symptoms 8

    Classification Analysis 9

Patient Population 11

Treatment Mechanisms 13

Treatment Effectiveness 14

Current Research/Clinical Evidence 15

Analysis and Depth 16

    Risks 16

    Limitations of Adverse Effects 17

    Neurotoxicity 18

    Capillary Leak Syndrome 19

    Hypotension 19

    Infection 19

    Fever 20

    Pain 20

Impacts 22

    Major Findings 22

    Limitations 22

    Research Challenges 24

    Accessibility 25

    Ethical/Social Deliberations 26

    Ponders 28

    Key Takeaways 29

    Relevance 30

    Future Research 30

Conclusion 31

Works Cited 32

Abstract

Neuroblastoma is a type of pediatric cancer that occurs in immature nerve cells, known as neuroblasts, but it is mostly found in adrenal glands, small organs that reside above the kidney (NCI Staff). Neuroblasts, in which neuroblastoma stems, can cause similar issues of rapid growth in the abdomen, chest, neck, or pelvis areas of the body. Neuroblastoma is the most common solid tumor cancer in children, the most common type of pediatric cancer in children less than one year old, and is classified as highly aggressive (Krysaal and Foster). Similarly, “high-risk” neuroblastoma is categorized as patients diagnosed with the addition of metastatic disease. Metastatic disease is a form of cancer that can spread to other parts of the body beyond its origin.  In 2015, the FDA approved dinutuximab as treatment for patients with High-Risk Neuroblastoma. This approval covers the use of dinutuximab for patients after first-line multiagent therapy; multimodality therapies such as surgery, chemotherapy, and radiation therapy for patients who have at least a partial response to the initial treatment given (NCI Staff). Unfortunately, roughly 700 people are diagnosed with neuroblastoma annually in the United States of America. (NCI Staff). The survival rate of high-risk neuroblastoma, even when treated with aggressive types of treatments, is 40-50%.  Utilizing dinutuximab has shown that 73% of patients survive following two years of receiving initial treatment.

Keywords: HR-NBL (High-Risk Neuroblastoma), Segmental Chromosomal Aberrations (SCA), metastatic, Granulocyte-macrophage Colony-stimulating Factor (GM-CSF), Aldesleukin (IL-2), Food and Drug Administration (FDA).

Introduction

Overview of Tumors

Tumors are the result of ungovernable growths which may or may not be cancerous. Such growths can stem from solid tissues like organs, muscles, and bone. According to Medical Oncology expert Dr. Robert J. Mayer in a 2019 publication, tumors can spread to tissues surrounding the origin through blood and lymph systems. 

There are two labels for solid tumors: malignant and benign. Solid malignant tumors are cancerous and can divide uncontrollably and contain cells that can start metastatic tumors in other parts of the body. Benign tumors are masses of non-cancerous cells that oftentimes do not require treatment because they do not spread to other healthy tissues.

Fig 1. Cleveland Clinic. “Tumor”. 2024

As for treatment options for tumors, benign tumors are frequently left without treatment unless they are in vulnerable areas of the body, such as the brain which can cause complications. Malignant tumors, on the other hand, are treated through the means of surgery, embolization, chemotherapy, etc as stated by the nonprofit American Medical Center, Cleveland Clinic in a 2024 research journal.  

Neuroblastoma

Neuroblastoma is regarded as the most common cancer diagnosed in children under the age of one. High-risk neuroblastoma, with the aid of The Children’s Oncology Group’s research in 2021, can be diagnosed when SCA’s are detected. Risk evaluation during diagnosis is crucial for determining what the necessary means of action are when assessing what treatment options are best. Along with the identification of SCA’s, high-risk neuroblastoma is diagnosed when the oncogene MYCN is found, immediately classifying the severity as high-risk and with the addition of being diagnosed after the 18th month mark. Patients diagnosed with low to intermediate-risk neuroblastoma have been estimated, by Pediatric Hematology Oncologist Julie Krystal and Pediatric Oncologist Jennifer H. Foster, to have an overall survival rate of 95% following the 5 years after diagnosis compared to the 60% for patients classified as high-risk in a 2023 report. Regrettably, roughly 50% of all patients diagnosed with neuroblastoma fall under the high-risk category.

Viable Treatment Options

Treatment for this highly aggressive pediatric cancer requires intense, multi-step treatments including chemotherapy, surgery, and stem cell transplants. For high-risk neuroblastoma, many sources indicate dinutuximab as a workable treatment plan. Dinutuximab is a drug used with GM-CSF, IL-2, and 130cis retinoic acid to treat patients diagnosed with the unfortunate condition (NCI Staff, 2025). Combining all materials, dinutuximab, GM-CSF, IL-2, and isotretinoin, it becomes an officially registered treatment option established with the US Food and Drug Administration for the treatment of high-risk neuroblastoma patients. 

Fig 2. St. Jude Children’s Research Hospital. “Neuroblastoma”. Together by St. Jude.org.While many low- or intermediate-risk cases respond well to treatment, pediatric patients with high-risk disease often need intensive multimodal therapy and still face risks of relapse, long-term complications, and death (National Cancer Institute; Cleveland Clinic). These persistent challenges highlight the importance of studying high-risk neuroblastoma within pediatric oncology.

Research Question:

   How does utilizing and adding dinutuximab to standard post-diagnosis therapy impact the survival and relapse rates in pediatric patients with high-risk neuroblastoma? 

Discussion

Topic Choice: Our Rationale

The choice of high-risk neuroblastoma as an area of investigation is motivated by the fact that this type of tumor is among the deadliest and most aggressive pediatric cancers despite medical advances made in this sphere. High-risk neuroblastoma arises from primitive sympathoadrenal ganglion cells derived from the neural crest and affects predominantly infants and young children. While low- and moderate-risk tumors may be successfully treated by means of chemotherapy, high-risk neuroblastoma should be treated using multimodality and aggressive therapies and is usually accompanied by high risks of relapse, toxicities, complications, and even mortality (National Cancer Institute; Cleveland Clinic). As a whole group, we aimed to understand how treatment strategies vary among patients and how factors such as response to therapy, side effects, and individual necessities influence clinical decisions. Examining these differences shows that successful cancer treatment goes beyond destroying cancer cells; it also involves careful consideration of each child’s overall health, quality of life, and therapy tolerability.

• I was interested in how treatment options for one of the most common childhood cancers varied from patient to patient. I wanted to know how allergies, side effects, or cultural differences influenced how a treatment like dinutuximab is administered.

• Having experienced being diagnosed and admitted into the hospital for a neurological disorder as a child, this topic seems very close to my heart. Waiting through long days in a lone hospital bed was agonizing until I discovered that my condition could be cured; I felt ecstatic. Spreading awareness of this condition seems to me the best way I can help other children and people feel confident in their health improvement. Through concise research, I want to share even a little more information to better advocate for pediatric patients. 

Diagnosis

Signs and Symptoms

Diagnosis involves a myriad of factors, including patient background, tumor data, and chromosomal abnormalities. Due to the condition’s broad effect in the body, signs and symptoms can vary according to the affected region.  Localized neuroblastoma provides minimal display of symptoms, which indicates clearer signs depicted in regional and metastatic neuroblastoma.

Adrenal Gland and Stomach: The condition may cause a painless abdominal mass and bowel movement abnormalities. Additional symptoms surrounding this portion of the body include belly pain and a mildly noticeable lump beneath the skin without tenderness at the touch (Mayo Clinic, 2025). 

Chest and Neck: The condition may cause irritation, inducing wheezing, breathing difficulties, and changes to eye structure. Other common symptoms in the highlighted body section include swelling. Specifically, eye structure changes can appear to be bulging or bruising and rapid muscle twitches surrounding the eyes (opsoclonus myoclonus) (American Cancer Society, 2025). 

Spine: The condition can prompt back pain from nerve compressions, difficulties with bowel movement/urination, and muscle fatigue surrounding the legs. In the case of spinal cord compression associated with the condition, immediate medical attention must be sought. If treated without haste, the symptoms can lead to permanent paralysis (Canadian Cancer Society, 2020). 

 Metastatic neuroblastoma is known as the distant spread of the condition, causing symptoms such as bone pain, dark circles around the eyes, fever, fatigue, painless lumps under the skin, and lack of regular weight growth (Mayo Clinic). According to a study by the International Neuroblastoma Risk Group, the typical age of diagnosis for the condition is between 18 months and 5 years of age (Colon and Chung). 

Classification Analysis

To classify and understand disease severity, physical examinations and imaging tests are conducted with various forms of medical equipment. Computerized tomography (CT) scans and magnetic resonance imaging (MRI) scans are used to measure tumor size and metastasis in the chest, abdomen, and pelvis. 123I-MIBG scans involve injecting a minuscule amount of radioactive iodine associated with the neuroblastoma chemical MIBG to identify tumorous cells. In 10-15% of cases, MIBG may not be an effective diagnostic measure, which requires positron emission tomography (PET) scans to recognize neuroblastoma metastasis by injecting a radiation compound into the patient. Bone marrow testing allows for content removal from the hip bone through aspiration, allowing for suction from a small needle, or biopsy, cutting a minuscule piece in the region under anesthesia. The tumor develops an excess amount of the hormone catecholamine, which can be measured in the urine through Urine VMA/HVA testing. Tissue biopsy provides the final confirmation for diagnosis, enabling treatment selection and identification of certain mutations. (CHOP) To determine classification before treatment, the International Neuroblastoma Risk Group Staging System can be used with two localized stages (L1 and L2) and two metastatic stages (M and MS). Stage L1 contains a locoregional tumor without IDRFs (image-defined risk factors), stage L2 is a locoregional tumor with one or more IDRFs, stage M holds a metastatic condition, and stage Ms is a stage L1 or L2 tumor with a metastatic condition limited to the skin/liver/bone marrow. Image-defined risk factors are essential to identifying tumor proximity to a major organ, thus providing information for surgical preparation (INRGDB).

Patient Population

High-Risk Neuroblastoma primarily impacts patients aged 18 months or older. Rare cases involve strong genetic markers in those younger than 18 months. (Colon and Chung) The condition is prevalent throughout the world, accounting for 8-10% of pediatric cancers and involving approximately 15% of pediatric cancer mortalities. A study conducted by authors in the National Institute of Health, based on data from the Global Burden of Disease (GBD) examined neuroblastoma prevalence among children aged 0-14 across 204 countries in 2021. Nationally, India maintained the highest number of neuroblastoma cases-685. The socio-demographic index portrayed the greatest prevalence of neuroblastoma in low-, low-middle, and middle- index regions. Children aged 10-14 years displayed the lowest incidence levels-6.3% globally (Nong et.al).

Fig 3. National Library of Medicine. “Global, regional, and national epidemiology of childhood neuroblastoma (1990–2021): a statistical analysis of incidence, mortality, and DALYs”. PubMed Central, 2024. 

Patients who are diagnosed with High-risk Neuroblastoma are pediatric patients commonly around 18 months and older. The majority of the patients who are diagnosed with High-risk Neuroblastoma are pediatric patients who are in early childhood. Additionally, 90% of all high–risk neuroblastoma cases are diagnosed before the patients become 10 years old. Males also tend to develop high-risk neuroblastoma more than females do because males are more commonly diagnosed with this type of pediatric cancer (Krystal and Foster).

Fig 4. National Library of Medicine. “Global, regional, and national epidemiology of childhood neuroblastoma (1990–2021): a statistical analysis of incidence, mortality, and DALYs”. PubMed Central, 2024. 

Treatment Mechanisms

Dinutuximab, known as a monoclonal antibody, serves as the primary treatment mechanism for high-risk neuroblastoma. It is lab-generated from the combination of a human IgG1 antibody and anti-GD2 antibody 14G2. Often overexpressed and located on neuroblastoma cells to bind tumor cells, disialoganglioside GD2 is the antigen targeted by dinutuximab. To inhibit cancer metastasis, the antibody depends on individual patient immune mechanisms. Leading to neuroblastoma cell lysis, dinutuximab binds to the GD2 surface and develops immune responses through the antibody-dependent cellular cytotoxicity (ADCC) and the complement-dependent cytotoxicity (CDC). In both processes, antibodies attach to target cells and use cytotoxic effector cells to destroy them. (Mastrangelo, et.al) In a hospital, 17.5 mg/m² of dinutuximab is given through an intravenous infusion (IV) over the course of 10 to 20 hours consecutively for four days. This is also dependent on the patient’s body surface area (aetna). Patients who have undergone multimodal therapy, including chemotherapy, surgery, and autologous stem cell transplantation, are qualified to receive the treatment. They must have gained a response to treatment methods to be administered the antibody (Hernadfoi et al.). In the present day, the FDA approved dinutuximab to treat patients with high-risk neuroblastoma. As indicated prior, the patient must have experienced first-line multimodality therapy (NCI). 

Treatment Effectiveness

The immunotherapy drug Dinutuximab (Unituxin) is proven to extend the lives of children living with high-risk neuroblastoma. 1,183 pediatric patients diagnosed with neuroblastoma participated in a clinical trial in which they were treated with Dinutuximab, given alongside two immune-boosting compounds and isotretinoin (Wang). After 5 years, a majority experienced event-free survival; when a patient is alive and free of tumor growth or recurrence. 2 years after the treatment showed 69% event-free survival and 84% survival overall, and 5 years after the treatment time showed 61% of the children event-free while 72% experienced overall survival (Wang). 

Fig 5. National Cancer Institute. “Study Confirms Dinutuximab Extends Life for Children with High-Risk Neuroblastoma”. Linda Wang, 2022. 

Research conducted and supported by Ami V. Desai, a pediatric oncologist from the University of Chicago, shows that tandem transplants have a higher rate of success than a single transplant. Combining this form of treatment with dinutuximab, however, was shown to be less effective, with a common symptom being pain. Following this observation, it has been concluded that dinutuximab is an effective treatment method when done without surgeries in rapid succession happening simultaneously. 

Current Research/Clinical Evidence

Current research from the Global Burden of Disease has shown that patients with high-risk neuroblastoma have significantly improved survival rates as compared to the 1990s. The shift is evident, with a show of 10 to 20% probability of survival to over 50% in modern day. This is attributed to the development of effective treatments over the span of three decades. Each year, there are approximately 5560 diagnosed cases of neuroblastoma worldwide. The average age of diagnosis is 17-18 months and 90% of diagnoses occur for patients under five years of age. The highest incidence rates of neuroblastoma were found in children under one year of age, holding 25.4% of diagnosed cases in 2021. Whereas children of 10-14 years reported the lowest rates of incidence, holding 6.3% of diagnosed cases in 2021(Nong, et.al). Studies conducted in the Journal of Clinical Oncology found that dinutuximab beta enables a significant reduction in tumors following six cycles of treatment. This is particularly beneficial in addition to chemotherapy, evident in improved objective response rates among patients.

Analysis and Depth

Risks

High-risk neuroblastoma is classified under stage M of the International Neuroblastoma Risk Group staging system. Patients may face relapse or refractory disease even with multiagent and high-dose chemotherapy, enabling few effective treatment options. Those who complete treatments may experience hearing loss, growth delays, fertility issues, and potential malignancy. Platinum-based chemotherapy serves as the primary contributor to hearing loss among patients, increasing chances of learning setbacks and social disabilities. Similar to many pediatric cancers, the condition develops risk of pulmonary and cardiac diseases due to exposure to chest radiotherapy, anthracycline chemotherapy, and busulfan. Treatment intensity leads to high levels of subsequent malignant neoplasms, known as secondary cancers, among survivors of high-risk neuroblastoma. Moreover, patients maintain higher chances of developing endocrinopathies, including hypothyroidism and hypogonadism. Stem cell transplantation increases exposures that lead to substandard linear growth and height. Testicular or ovarian gonadal failure derives from endocrine-based issues. As a result of early exposure to the condition, female patients may experience absent or delayed puberty (Dubois, et.al).

Fig 6. ASCO Publications. “High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes”. DuBois et,al, 2022. 

Limitations of Adverse Effects

Multiple severe side effects were associated with the dinutuximab combination, including neurotoxicity, allergic reactions, pain, infection, capillary leak syndrome, fever, and low blood pressure. The wide range of variability and severity of these adverse effects limit researchers' ability to generalize findings across all neuroblastoma patients. Dose reductions and study withdrawals occur as a result of treatment toxicities, which leaves the remaining data to be skewed towards more resilient subgroups. In addition, the heterogeneity across patients and tumors causes unpredictable side-effect manifestations across diverse ages and genetic profiles (National Cancer Institute).

Neurotoxicity 

When exposure to a natural or manmade toxic substance alters the normal functioning of the nervous system, leading to the disruption or even destruction of neurons (Cleveland Clinic). During the process of immunotherapy, the nervous system can face this damage when inflammatory chemicals or supercharged immune cells cause harm to the brain, spinal cord, or peripheral nerves. The two primary types of immunotherapy-induced neurologic toxicities are ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome) and irAEs (Immune-Related Adverse Events) (Sato et al.). ICANS, driven by blood-brain barrier breakdown and cytokine surges, is presented through symptoms like confusion, aphasia, and tremors. Driven by a loss of immune tolerance attacking neural tissue, neurological irAEs can be presented through symptoms such as encephalitis (brain inflammation), myasthenia gravis (an autoimmune disorder that disrupts communications between nerves and muscles), or peripheral neuropathies (damage to nerves outside the spinal cord and brain). Neurotoxicity is managed during immunotherapy by preventative pain control applied through intravenous opioids or oral gabapentin, neurological monitoring, and dose changes in response to reaction severity (Barone et al.).

Capillary Leak Syndrome

A side effect of dinutuximab immunotherapy where low blood pressure, swelling, and reduced urine output are caused by fluid and protein leakage from blood vessels into surrounding tissues. Symptoms of Capillary Leak Syndrome (CLS) may include hypotension, edema (swelling in hands, feet, or ankles), decreased intravascular volume, and decreased urine output (Armideo et al.). This side effect is managed through monitoring fluid balance, hemodynamic stability,  respiratory patterns, and infusion rate adjustments depending on the symptom severity (Secola et al.).

Hypotension

Caused by systemic vasodilation, capillary leak syndrome, or acute infusion reactions, Hypotension (low blood pressure) is a common side effect of Dinutuximab immunotherapy, with up to a 60% occurrence in patients (Armideo et al.). Common warning signs of hypotension are lightheadedness, fainting, nausea, extreme exhaustion, or breathing changes (Mayo Clinic). If a patient experiences hypotension during dinutuximab treatment, the infusion should immediately stop, and volume resuscitation (administration of plasma, blood, or other intravenous fluids to restore normal blood circulation and blood pressure) should be rapidly initiated. Other common management procedures for this side effect include proactive prehydration through about 10 mL saline infusions one hour before dinutuximab doses, clinical monitoring of vital signs, and dinutuximab infusion rate adjustments (Wheaton and Zalan).

Infection

During dinutuximab treatment, infection occurs primarily due to myelosuppression (bone marrow suppression, which suppresses the bone marrow's ability to produce healthy white blood cells. This leaves the body vulnerable to bacterial, viral, and fungal pathogens. Central venous catheters also cause infection risk as patients receiving continuous intravenous infusions face vulnerability to device-related infections through the use of central lines or ports, which can become direct entry points for skin bacteria into the bloodstream (Blom et al.). Common signs of infection are fever and chills, respiratory issues, urinary discomfort, and wound problems (itching, soreness, reddening) (Li and Zheng). The medical management of an infection amidst immunotherapy treatment requires the immediate interruption of the infusion, diagnostic workup to identify the specific invading pathogen, and promptly initiated antimicrobial therapy through the use of antibiotics, antivirals, and antifungals. 

Fever

There is an immune overstimulation that happens as a result of the infusion of the dinutuximab antibody. This activates the immune system, leads to the release of cytokines (a type of signaling protein), and results in the reset of the brain's thermostat. A fever can occur during or hours after the infusion process as a result of this overstimulation. To manage it, blood cultures are sent to rule out possible infection after a patient’s temperature begins to rise, a broad-spectrum antibiotic is given as other infusions are put on hold, and acetaminophen is pre-administered to the patient in anticipation of this common side effect (Armideo et al.).

Pain

Severe neuropathic pain is the most common result of dinutuximab infusions. Disialoganglioside GD2, found on the surface of neuroblastoma cells, is the primary target of dinutuximab. Because it is also expressed on neurons and peripheral sensory fibers, patients may experience neuropathic pain anywhere throughout the body (Yu et al.). In anticipation of this side effect, patients receive both a required IV bolus of a narcotic pain medication and a patient-controlled analgesia (PCA) infusion approximately 30 minutes before starting dinutuximab each day (Armideo et al.). Managing pain during the immunotherapy process requires a multimodal approach that relies on combining non-opioid pain relievers, nerve-pain medications, and pre-administered intravenous opioids delivered through methods like PCA.

Impacts

Major Findings

In 2015, the Food and Drug Administration (FDA) approved the use of dinutuximab as the primary form of therapy for pediatric cases of neuroblastoma. Dinutuximab is administered following the use of multimodality therapy such as surgery, chemotherapy, and radiation therapy (NCL, 2015).

Following three decades of constant treatment adjustment and improvement, including dinutuximab, positive response rates have climbed from 18.2% to 30.2% (Gray, J.C. et.al). Overall, with the now foundational use of dinutuximab as a form of combined treatment, survival rates are increasing and in the near future, a permanent cure may be discovered that has an epically low rate of recurring symptoms. 

Limitations

Though Dinutuximab serves a pivotal role in treatment methods, certain eligibility requirements inflict limitations on patients. This is highly dependent on the patient’s medical background and prior treatments. Disease progression prior to the GD2 antibody therapy and doses exceeding 17.5 mg/m² past 5 cycles enable restrictions to the treatment (molinahealthcare). Long term-effects of the antibody have shown improved survival rates. However, rare cases of dinutuximab beta therapy exposure may increase liver transaminase, hypoalbuminemia, and reduce blood count parameters. These effects are applicable in accordance with cytotoxic therapies (Achbergerova et.al). Furthermore, many patients experience cost and accessibility concerns due to high drug prices in the global market. On average, a complete treatment based on dinutuximab costs approximately $192,750. This significantly disrupts equal global access due to disparities between socio-economic classes. In a study conducted among 100 facilities across 59 countries, anti-GD2 therapy treatment was accessible in 93% of high-income centers and 21% in low-income centers (Papyan et.al). In spite of extensive research conducted on the effectiveness of dinutuximab on pediatric patients, certain questions remain unanswered. The addition of cytokines can aid in tumor lysis when combined with dinutuximab, but the significance remains unsettled. Moreover, the ideal infusion rate of anti-GD2 antibodies needs to be determined to address tolerability, which is currently being tested in international clinical trials (Dr. Reaman).

Fig 7. National Library of Medicine. “Dinutuximab beta in the treatment of high-risk neuroblastoma”. Achbergerová et.al, 2022. 

Research Challenges

Research challenges within the study of dinutuximab immunotherapy are adverse events, patient resistance or relapse, and treatment delivery optimization. 

Adverse events present a major challenge in the study of Dinutuximab because they cause severe physical distress, are diagnostically difficult to identify, and lead to complicated combinations of treatment protocols that vary from patient to patient (Barone et al.). The resulting pain pediatric patients face limits their treatment tolerance, requiring clinicians oftentimes to slow down, prolong, or stop immunotherapy. Identifying the specific side effect a patient is experiencing can be a complicated process due to the high symptom overlap between disease progression, infections, or the standard toxicity side effects. Pediatric patients' inability to differentiate and quantify neuropathic pain from the standard infusion distress also delays the identification of an adverse event. The combination of dinutuximab with multiple other background agents such as isotretinoin obscures which specific drug is the driving factor behind individual toxicities. The patient heterogeneity in the small pediatric sample sizes filled with children of diverse treatment backgrounds prevents the progression of accurate biomarker studies that help better understand a patient's response to toxicity (Pauken et al.).

Despite its substantial clinical success, over 40% of neuroblastoma patients develop resistance or fail to respond to the anti- GD2 therapy due to antigen loss, immunosuppressive microenvironments, and effector cell impairment (Liu et al.). Antigen loss is when cancer cells reduce the amount or completely discontinue the expression of the GD2 surface antigen, which means the antibody loses its binding target. When the network of cells and signals surrounding a tumor creates a barrier that blocks immune cells from destroying cancer cells, dinutuximab, an antibody that relies on immune cells such as the natural killer (NK), is weakened. In response to chemotherapy, there is a reduction in patients' immune cell counts, leading to an inability to properly recognize, bind to, and destroy cancer cells. Lack of response to the treatment and eventual relapse are among the primary research and clinical challenges within the study of Dinutuximab immunotherapy that are being fought with combinations that could potentially overcome resistance barriers and alternative anti-GD2 agents like dinutuximab beta or naxitamab (Furman).

The need to balance severe neuropathic pain with precise dosing schedules and patient quality of life poses treatment delivery optimization as a major research challenge to Dinutuximab immunotherapy.  To mitigate severe neuropathic pain during treatment, a co-administration of intravenous infusions of opioids or gabapentin by mouth needs to occur. Researchers must find a way to balance pain medication protocols in a way that maintains therapeutic efficiency without overwhelming a patient's tolerance. The duration of an infusion also affects the amount of pain a patient faces and the overall efficacy of the medication. Standardized short-term infusions result in pain spikes as a response to the toxicity, whereas long-term infusions (around 10 days) significantly reduce pain toxicity while sustaining the immune activity of the patient (Wheaton et al.). 

Accessibility

Over 200 children's hospitals and specialized cancer centers across the United States and Canada experience the distribution of Dinutuximab (Unituxin), with over 6,000 healthcare providers across these institutions that have been professionally trained to safely and effectively administer this treatment (Unituxin). Despite this, accessibility to Dinutuximab immunotherapy is still very highly restricted because it requires complex oncology infrastructure and prior insurance or financial clearance for a high-cost biological medication. 

The delivery of this treatment requires 10- to 20-hour intravenous infusions multiple times a day. This needs to be administered alongside continuous pain management infusions to deal with the neuropathic side effects. With a nearly 100% probability of a patient experiencing adverse events as a response to Dinutuximab immunotherapy (Yalçın et al.), most initial cycles of the treatment are given in a hospital setting where the patient can be closely monitored.

In order to gain approval from a patient’s health insurance provider, extensive documentation of diagnosis, phase of treatment, and logistical coordination is required beforehand and can often become an access barrier to the patient receiving treatment. The baseline cost for a full multi-cycle course of anti-GD2 therapy for the dinutuximab drug alone ranges from $140,000 to $190,000. This highlights the substantial financial burden these therapies would impose on families who go through with the treatment. If a family chooses to rely on their health insurance, prior authorization for treatment is only granted after the pediatric oncologist provides clinical notes that prove the pediatric patient is under 21 years old, has high-risk neuroblastoma, and has achieved at least some form of response to first-line induction therapy. Once these oncology notes are received, the time required for companies to go through and complex oncology protocols can stall critical maintenance therapies that could have already been underway (Jones et al.). If a physician prescribes a non-standardized dinutuximab combination to improve a patient’s response to treatment, insurers may also deny coverage under the belief that it is investigational, forcing a lengthy appeal process defending a style of treatment that could ultimately benefit the patient.

Ethical/Social Deliberations

Ethical and Social considerations surrounding treating high-risk neuroblastoma with the dinutuximab drug include proxy decision-making, equitable access, and family quality of life. 

According to the American Cancer Society, neuroblastoma is the most common cancer diagnosed in a child during their first year of life, and about 75% to 89% of all neuroblastoma patients are diagnosed before the age of 5. Since infants and young children are the predominant patients, their parents are often left with the decision of consenting to painful treatment plans and regimens without the full comprehension of the child who must undergo it.

Dinutuximab treatment consists of 5 total treatment cycles that average a total length of 4 to 6 months (Cabral et al.). All throughout this time, a patient should go through specialized immunotherapy, inpatient monitoring, and specialized pain management. 65% of treatment centers in low- and middle-income countries completely lack access to anti- GD2 immunotherapies due to high costs with no compensation. In comparison to 93% in high-income countries, only 21% of LMICs (low- and middle-income countries) offer frontline maintenance with anti-GD2 therapy. This is due to the economic advantage high-income countries have, as they rely on government or insurance coverage; meanwhile, low-income regions are forced to rely on funds that come almost entirely from out-of-pocket payments or charity support (Papyan et al.).

The treatment cycles of immunotherapy often result in a disruption to the lives of the families affected by it. A family’s stability, including parental employment, educational development of patients and siblings, and the social development of patients and siblings, can all be heavily affected by a continuous pattern of prolonged hospital visits and outpatient infusions. A child experiencing the intensive treatment will face long-term social and educational interruptions during critical formative years due to the active treatment cycles shadowing their early stages of development. Long-term resilience from survivors of neuroblastoma and their families is still met with aftereffects such as lingering anxiety about relapse or future health issues (Tan et al.).

Ponders

Remaining questions in the study of high-risk neuroblastoma being treated with dinutuximab are treatment optimization through most effective dosing strategies, clarity on the benefits of drug combinations, and long-term impacts faced by survivors. 

In a recent St. Jude study that used the newer anti-GD2 variant known as hu14.18K322A, it has been unclear whether its better-yielding results in comparison to dinutuximab are due to its higher dose magnitude or because it is a better antibody (St. Jude Children’s Research Hospital). In the further assessment of optimal dosing, researchers are working to clarify if an earlier timing of Dinutuximab administration improves survival rates compared to it being given in the standard post-consolidation phase. Furthermore, in order to maximize anti-tumor efficacy while effectively mitigating neuropathic pain, the length of dosing periods during infusion is being refined into more continuous lengths instead of short-term (Ladenstein).

The use of cytokines within Dinutuximab immunotherapy is to boost the patient's immune system so it can better find and destroy cancer cells. In an attempt to better understand how to utilize cytokines, researchers are trying to clarify whether co-administering them increases survival benefits, or only increases toxicity. It is also being determined how to treat tumors that downregulate or altogether resist anti-GD2 combinations. To fight against relapse,  multi-agent combinations could potentially be used for patients who progress despite dinutuximab exposure being explored as well. Common antibody-chemotherapy combinations are TEMIRI, TOTEM, or HITS (Raiser et al.).

Since Neuroblastoma is a pediatric cancer, the effects of dinutuximab immunotherapy on pediatric patients could have long-term or even lifelong impacts on their growth and development. Post-treatment growth that tracks standard pediatric measurements (height, weight, body mass) in addition to skeletal maturation and hormone screening requires continual long-term surveillance to decipher relationships between growth patterns and treatment history of recovered neuroblastoma patients. Chronic health outcomes of pediatric survivors are being further studied as well, with current studies showing noticeable rates of autoimmune disease and chronic diarrhea present in survivors attributed to the antibody treatment (Flaadt et al.).

Key Takeaways

The monoclonal antibody dinutuximab acts by binding to the molecule labeled as GD2. GD2 is a disialoganglioside molecule, a tumor-associated antigen in regard to cancer that can be found on cell membranes. 

Regardless of the recent introduction of dinutuximab as treatment, it has already shown prominent signs of effectiveness, with 73% of patients surviving beyond two years of initial treatment compared to 58% without its use (NCL, 2015). 

Confirmed through hundreds upon hundreds of trials, it has been proven in 2022 that dinutuximab is a viable treatment option to elongate the life of patients diagnosed with high-risk neuroblastoma. The first stages of the trials provided evidence that the combination of dinutuximab with other existing treatments following the 2015 FDA approval led to the accumulation of patients who had no evidence of recurring symptoms two years after initiating the new treatment (Wang, 2022). 

Relevance

Since its approval by the FDA in 2015, dinutuximab has proven time and time again that it can elongate the lifespan of pediatric patients diagnosed with the condition, high-risk neuroblastoma. This is crucial to run more trials in the hopes of finding a cure or another method to better the quality of life a patient can have and to lead to interconnected macrodiscoveries that can be used to treat other conditions with similar characteristics. In addition, the use of dinutuximab has shown many cases of relapse prevention, minimizing residual disease in patients beyond treatment and recovery (ASCO Post Staff, 2016). 

Future Research

In Hungarian clinical trial settings, there is evidence of multiple cases of initial misdiagnoses. When research is completed by Márk Hernádfői et. al, rural diagnostic delays in pediatric oncology clinics may be reduced drastically, providing a method to systematically diagnose a patient rapidly to evaluate optimal treatment options. In extension, this can lead to higher survival rates because treatment options can be personalized sooner. In conclusion, with the success of future trials, the efficacy of testing different dinutuximab variations for different patient types can be improved, leading to branching discoveries and improved rates of patient survivability and quality of life (Márk Hernádfői et. al, 2025).

Conclusion

High-Risk Neuroblastoma is the most common pediatric cancer diagnosed in patients younger than 12 months. An aggressive form of cancer that categorizes roughly half of its carriers as high-risk, in addition, giving a less than desired survivability rate beyond five years once diagnosed. Yet, after decades of research and fine-tuning treatment options, dinutuximab, a drug, has been applied in clinical trials and has so far been successful. In its success, raising the survival rate beyond two and five years, respectively. Pediatric high-risk neuroblastoma requires more research to ensure patients can receive optimized treatment that is specific to any underlying conditions that may be present. Overall, our research presents what is currently known and understood of the condition, how it impacts patients, and what can be continued to work on. Real-life application of our research lies in advocacy and awareness, providing information to detect symptoms soon, and supporting ongoing research to drive for acclimated treatments with the use of dinutuximab. Future research in multiple aspects should focus on early detection without misdiagnoses to refine treatment mechanisms, reduce recurring symptoms, and to improve the overall quality of life of all affected by this condition, especially pediatric patients. 

Works Cited 

Achbergerová, Monika, et al. "Dinutuximab Beta in the Treatment of High-risk Neuroblastoma." Medicine, vol. 101, no. 4, 28 Jan. 2022, p. e28716, https://doi.org/10.1097/md.0000000000028716. Accessed 29 July 2026.

Aetna. "Dinutuximab (Unituxin)." aetna, 23 Oct. 2025, www.aetna.com/cpb/medical/data/800_899/0895.html. Accessed 29 July 2026.

American Cancer Society. "Signs and Symptoms of Neuroblastoma." Cancer.org, 26 June 2025, www.cancer.org/cancer/types/neuroblastoma/detection-diagnosis-staging/signs-and-symptoms.html. Accessed 29 July 2026.

The APSO Post Staff. "Approval of Dinutuximab for High-Risk Neuroblastoma: Lessons Learned in Expediting the Development of Pediatric Cancer Drugs." The ASCO Post, Dec.-Jan. 2016, ascopost.com/issues/december-10-2016/approval-of-dinutuximab-for-high-risk-neuroblastoma-lessons-learned-in-expediting-the-development-of-pediatric-cancer-drugs/. Accessed 29 July 2026.

Armideo, RN, CRNP, et al. "Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications." Journal of the Advanced Practitioner in Oncology, vol. 8, no. 1, 1 Feb. 2017, https://doi.org/10.6004/jadpro.2017.8.1.4. Accessed 29 July 2026.

Bagatell, Rochelle. "Hereditary Neuroblastoma." Children's Hospital of Philadelphia, www.chop.edu/conditions-diseases/hereditary-neuroblastoma. Accessed 29 July 2026.

Barone, Giuseppe, et al. "Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance." Pediatric Drugs, vol. 23, no. 6, 20 Sept. 2021, pp. 537-48, https://doi.org/10.1007/s40272-021-00469-9. Accessed 29 July 2026.

Blom, Thomas, et al. "Treatment-Related Toxicities during Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients." Frontiers in Oncology, vol. 10, 17 Feb. 2021, https://doi.org/10.3389/fonc.2020.601076. Accessed 29 July 2026.

Boston's Children Hospital. "Neuroblastoma." Boston's Children Hospital, www.childrenshospital.org/conditions-treatments/neuroblastoma. Accessed 29 July 2026.

Campos Cogo, Sheron, et al. "An Overview of Neuroblastoma Cell Lineage Phenotypes." Experimental Biology and Medicine, vol. 245, no. 18, 12 Aug. 2020, pp. 1637-47, https://doi.org/10.1177/1535370220949237. Accessed 29 July 2026.

Canadian Cancer Society. "Symptoms of neuroblastoma." Cancer.ca, Jan. 2020, cancer.ca/en/cancer-information/cancer-types/neuroblastoma/signs-and-symptoms. Accessed 29 July 2026.

Cleveland Clinic. "Neuroblastoma." Cleveland Clinic. Cleveland Clinic, my.clevelandclinic.org/health/diseases/14390-neuroblastoma. Accessed 29 July 2026.

Colon, Nadja C., and Dai H. Chung. "Neuroblastoma." Advances in Pediatrics, vol. 58, no. 1, 2011, pp. 297-311, https://doi.org/10.1016/j.yapd.2011.03.011. Accessed 29 July 2026.

Cupit-Link, Margaret, and Sara M. Federico. "Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in All Cycles of Induction." Cancers, vol. 15, no. 18, 18 Sept. 2023, p. 4609, https://doi.org/10.3390/cancers15184609. Accessed 29 July 2026.

D'Hebron, Vall. "An international clinical trial demonstrates the benefit of combining chemotherapy and immunotherapy in the treatment of neuroblastoma." BioTech, 13 Feb. 2026, biotech-spain.com/en/articles/an-international-clinical-trial-demonstrates-the-benefit-of-combining-chemotherapy-and-immunotherapy-in-the-treatment-of-neuroblastoma/. Accessed 29 July 2026.

DuBois, Steven G., et al. "High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes." American Society of Clinical Oncology Educational Book, no. 42, July 2022, pp. 768-80, https://doi.org/10.1200/edbk_349783. Accessed 29 July 2026.

---. "High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes." American Society of Clinical Oncology Educational Book, no. 42, July 2022, pp. 768-80, https://doi.org/10.1200/edbk_349783. Accessed 29 July 2026.

Escalante Romero, Lorena, et al. "Efficacy and Safety of the Use of Dinutuximab in Newly Diagnosed or Relapse High Risk Neuroblastoma: Single Arm Systematic Review and Meta-analysis." Journal of Clinical Oncology, vol. 42, no. 16_suppl, 1 June 2024, p. 10044, https://doi.org/10.1200/jco.2024.42.16_suppl.10044. Accessed 29 July 2026.

European Journal of Cancer. 2024, www.ejcancer.com/article/S0959-8049(24)00157-6/fulltext. Accessed 29 July 2026.

Flaadt, Tim, et al. "Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment including Anti-GD2 Immunotherapy: A Retrospective Cohort Study." Cancers, vol. 17, no. 1, 5 Jan. 2025, p. 149, https://doi.org/10.3390/cancers17010149. Accessed 29 July 2026.

Furman, Wayne L. "Monoclonal Antibody Therapies for High Risk Neuroblastoma." Biologics: Targets and Therapy, vols. Volume 15, June 2021, pp. 205-19, https://doi.org/10.2147/btt.s267278. Accessed 29 July 2026.

---. "Monoclonal Antibody Therapies for High Risk Neuroblastoma." Biologics: Targets and Therapy, vols. Volume 15, June 2021, pp. 205-19, https://doi.org/10.2147/btt.s267278. Accessed 29 July 2026.

Hernádfői, Márk, et al. "Dinutuximab Beta for the Treatment of High-Risk Neuroblastoma: Data from the Hungarian Pediatric Oncology Network." Journal of Clinical Medicine, vol. 14, no. 18, 20 Sept. 2025, p. 6641, https://doi.org/10.3390/jcm14186641. Accessed 29 July 2026.

---. "Dinutuximab Beta for the Treatment of High-Risk Neuroblastoma: Data from the Hungarian Pediatric Oncology Network." Journal of Clinical Medicine, vol. 14, no. 18, 20 Sept. 2025, p. 6641, https://doi.org/10.3390/jcm14186641. Accessed 29 July 2026.

Hesko, Caroline, et al. "Neurocognitive Outcomes in Adult Survivors of Neuroblastoma: A Report from the Childhood Cancer Survivor Study." Cancer, vol. 129, no. 18, 18 May 2023, pp. 2904-14, https://doi.org/10.1002/cncr.34847. Accessed 29 July 2026.

Hoy, Sheridan M. "Dinutuximab: A Review in High-Risk Neuroblastoma." Targeted Oncology, vol. 11, no. 2, 19 Feb. 2016, pp. 247-53, https://doi.org/10.1007/s11523-016-0420-2. Accessed 29 July 2026.

INRG Staging System. "INRGSS: International Neuroblastoma Risk Group Staging System." INRG, inrgdb.org/neuroblastoma-information/staging-system/. Accessed 29 July 2026.

Keyel, Michelle E., and C. Patrick Reynolds. "Spotlight on Dinutuximab in the Treatment of High-risk Neuroblastoma: Development and Place in Therapy." Biologics: Targets and Therapy, vols. Volume 13, Dec. 2018, pp. 1-12, https://doi.org/10.2147/btt.s114530. Accessed 29 July 2026.

Krystal, Julie, and Jennifer H. Foster. "Treatment of High-Risk Neuroblastoma." Children, vol. 10, no. 8, 28 July 2023, p. 1302, https://doi.org/10.3390/children10081302. Accessed 29 July 2026.

---. "Treatment of High-Risk Neuroblastoma." Children, vol. 10, no. 8, 28 July 2023, p. 1302, https://doi.org/10.3390/children10081302. Accessed 29 July 2026.

Lerman, Benjamin J., et al. "Progression-Free Survival and Patterns of Response in Patients with Relapsed High-Risk Neuroblastoma Treated with Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor." Journal of Clinical Oncology, vol. 41, no. 3, 20 Jan. 2023, pp. 508-16, https://doi.org/10.1200/jco.22.01273. Accessed 29 July 2026.

Lode, Holger N., et al. "Dinutuximab Beta vs. Historical Controls in the Maintenance Therapy of Relapsed Neuroblastoma: Unadjusted and Adjusted Indirect Comparison." ISPOR, vol. 28, no. S2, 2025, www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2025/poster-session-2-2/dinutuximab-beta-vs-historical-controls-in-the-maintenance-therapy-of-relapsed-neuroblastoma-unadjusted-and-adjusted-indirect-comparison#:~:text=CONCLUSIONS:%20Dinutuximab%20beta%20significantly%20extends,unadjusted%20and%20adjusted%20indirect%20comparisons. Accessed 29 July 2026.

Mastrangelo, Stefano, et al. "Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients." International Journal of Molecular Sciences, vol. 22, no. 23, 23 Nov. 2021, p. 12648, https://doi.org/10.3390/ijms222312648. Accessed 29 July 2026.

Mayer, Robert J. "Tumor vs Cancer: What You Need to Know." Dana-Farber Cancer Institute, 16 May 2018. Dana-Farber Cancer Institute, blog.dana-farber.org/insight/2018/05/difference-cancer-tumor/. Accessed 29 July 2026.

MAYO Clinic. "Neuroblastoma." MAYO Clinic, www.mayoclinic.org/diseases-conditions/neuroblastoma/symptoms-causes/syc-20351017. Accessed 29 July 2026.

Mohd, Ahmed Bassam, et al. "Safety and Efficacy of Dinutuximab in the Treatment of Neuroblastoma: A Review." Journal of Research in Medical Sciences, vol. 28, no. 1, Sept. 2023, https://doi.org/10.4103/jrms.jrms_727_22. Accessed 29 July 2026.

Mora, Jaume. "Dinutuximab for the Treatment of Pediatric Patients with High-risk Neuroblastoma." Expert Review of Clinical Pharmacology, vol. 9, no. 5, 21 Mar. 2016, pp. 647-53, https://doi.org/10.1586/17512433.2016.1160775. Accessed 29 July 2026.

---. "Dinutuximab for the Treatment of Pediatric Patients with High-risk Neuroblastoma." Expert Review of Clinical Pharmacology, vol. 9, no. 5, 21 Mar. 2016, pp. 647-53, https://doi.org/10.1586/17512433.2016.1160775. Accessed 29 July 2026.

National Cancer Institute. "Neuroblastoma Treatment (PDQ®)–Health Professional Version." National Cancer Institute, 28 Apr. 2025. Cancer.gov, www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq#top. Accessed 29 July 2026.

NCI Staff. "FDA Approves First Therapy for High-Risk Neuroblastoma." National Cancer Institute, 27 Mar. 2015. National Cancer Institute, www.cancer.gov/news-events/cancer-currents-blog/2015/dinutuximab-neuroblastoma. Accessed 29 July 2026.

Nong, Jusen, et al. "Global, Regional, and National Epidemiology of Childhood Neuroblastoma (1990–2021): A Statistical Analysis of Incidence, Mortality, and DALYs." EClinicalMedicine, vol. 79, Jan. 2025, p. 102964, https://doi.org/10.1016/j.eclinm.2024.102964. Accessed 29 July 2026.

---. "Global, Regional, and National Epidemiology of Childhood Neuroblastoma (1990–2021): A Statistical Analysis of Incidence, Mortality, and DALYs." EClinicalMedicine, vol. 79, Jan. 2025, p. 102964, https://doi.org/10.1016/j.eclinm.2024.102964. Accessed 29 July 2026.

Olgun, Nur, et al. "Dinutuximab Beta plus Conventional Chemotherapy for Relapsed/refractory High-risk Neuroblastoma: A Single-center Experience." Frontiers in Oncology, vol. 12, 23 Dec. 2022, https://doi.org/10.3389/fonc.2022.1041443. Accessed 29 July 2026.

Papyan, Ruzanna, et al. "The Price of Survival: Global Inequities in Anti‐GD2 Immunotherapy for Neuroblastoma." Pediatric Blood & Cancer, vol. 73, no. 4, 23 Jan. 2026, https://doi.org/10.1002/1545-5017.70152. Accessed 29 July 2026.

---. "The Price of Survival: Global Inequities in Anti‐GD2 Immunotherapy for Neuroblastoma." Pediatric Blood & Cancer, vol. 73, no. 4, 23 Jan. 2026, https://doi.org/10.1002/1545-5017.70152. Accessed 29 July 2026.

Pauken, Kristen E., et al. "Adverse Events following Cancer Immunotherapy: Obstacles and Opportunities." Trends in Immunology, vol. 40, no. 6, June 2019, pp. 511-23, https://doi.org/10.1016/j.it.2019.04.002. Accessed 29 July 2026.

Secola, Rita, et al. "The Role of Nursing Professionals in the Management of Patients with High-Risk Neuroblastoma Receiving Dinutuximab Therapy." Journal of Pediatric Oncology Nursing, vol. 34, no. 3, 6 Jan. 2017, pp. 160-72, https://doi.org/10.1177/1043454216680595. Accessed 29 July 2026.

St.Jude Children's Research Hospital. "Neuroblastoma." together.stjude.org, together.stjude.org/en-us/conditions/cancers/neuroblastoma.html?sc_cid=-together_evergreen_traffic_search_neuroblastoma-fy25-google-search-paid-responsive-neuroblastoma_general&gad_source=1&gad_campaignid=22634041372&gbraid=0AAAAACYxWIcsHL69yyVTiKKrgTHpLCBwW&gclid=Cj0KCQjw94bTBhDQARIsAN3vv0za3REkfY5NQeH6paBUBk_cjni64nYhTa2-op2Vm4x3CqsGWvydsooaAk0REALw_wcB. Accessed 29 July 2026.

Study Confirms Dinutuximab Extends Life for Children with High-Risk Neuroblastoma. 6 Sept. 2022. National Cancer Institute, www.cancer.gov/news-events/cancer-currents-blog/2022/study-confirms-dinutiximab-high-risk-neuroblastoma. Accessed 29 July 2026.

Tan, Jessica, et al. "Neuroblastoma Survivors' Self-reported Late Effects, Quality of Life, Health-care Use, and Risk Perceptions." Palliative and Supportive Care, vol. 22, no. 2, 14 June 2023, pp. 296-305, https://doi.org/10.1017/s1478951523000615. Accessed 29 July 2026.

Trahair, T. N., et al. "Long-term Outcomes in Children with High-risk Neuroblastoma Treated with Autologous Stem Cell Transplantation." Bone Marrow Transplantation, vol. 40, no. 8, 27 Aug. 2007, pp. 741-46, https://doi.org/10.1038/sj.bmt.1705809. Accessed 29 July 2026.

University of Birmingham. "Dinutuximab beta plus chemotherapy shrinks neuroblastoma tumors in children." News Medical Life Sciences, 12 Dec. 2025, www.news-medical.net/news/20251212/Dinutuximab-beta-plus-chemotherapy-shrinks-neuroblastoma-tumors-in-children.aspx. Accessed 29 July 2026.

Utilization Management Committee. "Drug Policy: Unituxin™ (dinutuximab)." Molina Healthcare, 12 July 2023, www.molinahealthcare.com/-/media/Molina/PublicWebsite/PDF/Providers/oh/medicaid/policies/Unituxin-dinutuximab-Policy-No-UM-ONC-1387-0624.ashx. Accessed 29 July 2026.

Yalçın, B., et al. "Adverse Events Associated with Dinutuximab-beta Treatment in High-risk Neuroblastoma: Hacettepe Experience." EJC Paediatric Oncology, vol. 7, June 2026, p. 100452, https://doi.org/10.1016/j.ejcped.2025.100452. Accessed 29 July 2026.

Yu, Alice L., et al. "Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma." New England Journal of Medicine, vol. 363, no. 14, 30 Sept. 2010, pp. 1324-34, https://doi.org/10.1056/nejmoa0911123. Accessed 29 July 2026.